{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.1","upperLimit":"8.3","value":"3.7"},{"comment":"The upper bound of the 95% confidence interval has not yet been reached.","groupId":"OG001","lowerLimit":"1.0","upperLimit":"NA","value":"2.3"},{"groupId":"OG002","lowerLimit":"3.0","upperLimit":"9.6","value":"4.2"},{"groupId":"OG003","lowerLimit":"3.9","upperLimit":"5.8","value":"4.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"18"}],"units":"Participants"}],"description":"Progression-free survival time is defined as the time from registration to progression or death due to any cause. Progression is defined for myeloma as Any one or more of the following: Increase of 25% from lowest value in, Serum M-component (absolute increase must be ≥ 0.5 g/dl), Serum M-component increase ≥ 1 g/dl, if lowest M component was ≥ 5 g/dl,Urine M-component (absolute increase must be ≥ 200 mg/24 h), Bone marrow plasma cell percentage (absolute % must be ≥10%) Or any one or more of the following felt related to the underlying clonal plasma cell proliferative disorder: Development of new soft tissue plasmacytomas or bone lesions, Hypercalcemia (≥11.5 mg/dl) Decrease in hemoglobin of ≥2 g/dl, Serum creatinine level ≥2 mg/dl. Progression is defined for lymphoma as any new lesion or increase by ≥50% of previously involved sites from nadir. The median and 95% confidence intervals are estimated using the method of Kaplan-Meier.","dispersionType":"95% Confidence Interval","groups":[{"description":"Lymphoma patients receive 20 mg/day panobinostat (LBH589) PO on days 1, 3, 5, 15, 17, and 19 and 5 mg/day everolimus PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Phase II (Lymphoma Patients Receiving 20 mg LBL589)"},{"description":"Myeloma patients receive 20 mg/day panobinostat (LBH589) PO on days 1, 3, 5, 15, 17, and 19 and 5 mg/day everolimus PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Phase II (Myeloma Patients Receiving 20 mg LBH589)"},{"description":"Lymphoma patients receive 30 or 40 mg/day panobinostat (LBH589) PO on days 1, 3, 5, 15, 17, and 19 and 5 mg/day everolimus PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG002","title":"Phase II (Lymphoma Patients Receiving 30/40 mg LBH589)"},{"description":"Myeloma patients receive 30 or 40 mg/day panobinostat (LBH589) PO on days 1, 3, 5, 15, 17, and 19 and 5 mg/day everolimus PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG003","title":"Phase II (Myeloma Patients Receiving 30/40 mg LBH589)"}],"paramType":"MEDIAN","populationDescription":"Patients who were enrolled in and completed Phase II and treated at a starting dose of 20 mg or 30/40 mg LBH589 were evaluated in this analysis.","reportingStatus":"POSTED","timeFrame":"Time from registration to progression or death due to any cause, assessed up to 2 years post-treatment","title":"Progression-free Survival (Phase II)","type":"SECONDARY","unitOfMeasure":"months"}